Study of Azacitidine to Treat Relapsed or Refractory Multiple Myeloma
Status:
Terminated
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
This is a Phase II trial evaluating the overall response rate, safety and tolerability to
azacitidine in patients with relapsed or refractory multiple myeloma.